Pharmaceutical organizations face growing pressure to maintain post‑approval compliance across multiple markets while managing increasing volumes of safety- and regulatory‑driven change. Local requirements, fragmented safety and regulatory operations, variable workload peaks, and limited in‑country expertise can slow updates, create inconsistencies, and increase inspection risk. This white paper explores how integrating Local Qualified Person for Pharmacovigilance (LQPPV) oversight with lifecycle management under a unified operating model helps sponsors improve governance, reduce duplication, and accelerate global execution. It also outlines how adaptive resourcing and applied, inspection‑ready AI can support scalable post‑approval workflows without requiring organizational restructuring or large technology overhauls.
Download the white paper to learn how a synergistic approach to LQPPV, lifecycle management, adaptive resourcing, and applied AI can help your organization improve post‑approval efficiency, strengthen inspection readiness, and stay ahead of evolving global regulatory expectations.
Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.
.svg){kind=icon}
